

Date: 15 February 2024

To The Manager Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001

Dear Sir/Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Sub: Pursuant to the requirement under regulation 30 of SEBI (Listing Obligation and Disclosure requirements) Regulation 2015 ("SEBI (LODR) Regulations, 2015"), disclosure of acquisition of stake in the Anugraha Chemicals ("the Firm").

Ref: Outcome of Board Meeting and intimation dated January 17, 2023

This is in furtherance to our intimations 17th January 2023, 18th August 2023, 11th January 2024, 09th February 2024 and 10th February 2024 regarding investment and the update on the same in Anugraha Chemicals ("the Firm"), a Partnership Firm, registered under the Karnataka Partnership (Registration of Firms), Rules, 1954 by acquiring 51% stake in multiple tranches.

Further, we would like to inform you that the Company vide its investment through different tranches has now additionally acquired 9.35% of partnership interest totaling 50.60% out of the said proposed investment of 51% till date.

The above investment is as per the investment agreement entered between the company and the firm dated 25th January, 2023 as approved by the Board at their meeting held on 17th January, 2023.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given in the enclosed **Annexure I.**

This is for your kind information and record.

Thanking you

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Head-Legal)



ANNEXURE 1

Brief details of the investment:

Name of the target entity, details in brief such as size, turnover etc.;	Anugraha Chemicals, a Partnership Firm, registered under the Karnataka Partnership (Registration of Firms), Rules, 1954, is having capital of Rs. 10,00,000/- (Rupees Ten Lakh Only) and turnover of Rs. 11,37,37,272/- (Rupees Eleven Crore Thirty Seventy Leikh Thirty Seven Theorem Theorem 1		
	Seventy Lakh Thirty-Seven Thousand Two Hundred Seventy-Two Only) as per the Audited Financial Statement for the Financial Year 2022-23.		
Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of Interest and details thereof and whether the same is done at "arm's length".	Not Applicable		
Industry to which the entity being acquired belongs;	Anugraha Chemicals are engaged in Contract Manufacturing and Manufacturing of APIs, Intermediates and Fine Chemicals.		
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisitions of target entity, if its business is outside the main line of business of the listed entity);	The Company, in order to expand its business and to support Anugraha Chemicals ("the Firm"), have agreed to acquire 51% stake in the Firm. This will help company to achieve its objective of GMP Manufacturing on the other hand it will help the Firm to reach out the larger market and acquire large customer base.		
Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable		
Indicative time period for completion of the acquisition	The acquisition and investment will be in multiple tranches as outlined in the Investment Agreement.		
Nature of consideration – whether cash consideration or share swap and details of the same;	Cash consideration		
Cost of acquisition or the price at which the shares are acquired;	The aggregate proposed investment is Rs. 5,14,08,000/- (Rupees Five Crores Fourteen Lakhs Eight Thousand) being 51% partnership interest stake in the firm in multiple tranches.		

Pharmaids Pharmaceuticals Limited

Percentage of shareholding/control acquired	The Compar	ny has acc	uired 50.60%	
and/or number of shares acquired;	partnership interest in the Firm as on date out			
-	of the said proposed investment of 51%.			
Brief background about the entity acquired in	Anugraha Chemicals, a Partnership Firm,			
terms of products/line of business acquired,	registered under the Karnataka Partnership			
date of incorporation, history of last 3 years	(Registration of firms), Rules, 1954, was			
turnover, country in which the acquired	established in 1991 and has a rich experience			
entity has presence and any other significant	of over two and half decades in the			
information (in brief)	pharmaceutical industry. Anugraha			
	Chemicals are engaged in Contract			
	Manufacturing and Manufacturing of APIs,			
	Intermediaries and Fine Chemicals. Turnover and net profits/loss of Anugraha Chemicals for the last three financial years are as follows:			
	Financial	Net Profit	Turnover	
	Year	(In Rs.)	(In Rs.)	
	2022-23	13,64,544	11,37,37,272	
	2021-22	12,71,130	12,42,40,352	
	2020-21	15,35,760	11,35,21,731	

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Head-Legal)